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Abstract
Background: Sepsis is a global inflammatory disease that causes death. It has been reported that mesenchymal
stem cell (MSC) treatment can attenuate inflammatory and septic symptoms. In this study, we investigated how
interactions between neutrophils and human umbilical cord blood (hUCB)-MSCs in the liver of septic mice are
involved in mitigating sepsis that is mediated by MSCs. Accordingly, we aimed to determine whether hUCB-MSC
application could be an appropriate treatment for sepsis.
Methods: To induce septic condition, lipopolysaccharide (LPS) was intraperitoneally (i.p.) injected into mice 24 h
after the intravenous (i.v.) injection of saline or hUCB-MSCs. To determine the effect of hUCB-MSCs on the immune
response during sepsis, histologic analysis, immunoassays, and two-photon intravital imaging were performed 6 h
post-LPS injection. For the survival study, mice were monitored for 6 days after LPS injection.
Results: The injection (i.v.) of hUCB-MSCs alleviated the severity of LPS-induced sepsis by increasing IL-10 levels
(p < 0.001) and decreasing mortality (p < 0.05) in septic mice. In addition, this significantly reduced the recruitment
of neutrophils (p < 0.001) to the liver. In hUCB-MSC-treated condition, we also observed several distinct patterns of
dynamic interactions between neutrophils and hUCB-MSCs in the inflamed mouse liver, as well as vigorous interactions
between hepatic stellate cells (HSCs or ito cells) and hUCB-MSCs. Interestingly, hUCB-MSCs that originated from humans
were not recognized as foreign in the mouse body and consequently did not cause graft rejection.
Conclusions: These distinct interaction patterns between innate immune cells and hUCB-MSCs demonstrated that
hUCB-MSCs have beneficial effects against LPS-induced sepsis through associations with neutrophils. In addition, the
immunomodulatory properties of hUCB-MSCs might enable immune evasion in the host. Taken together, our results
suggest the prospects of hUCB-MSCs as a therapeutic tool to inhibit inflammation and alleviate pathological immune
responses such as sepsis.
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Backgrounds
Sepsis, the result of systemic inflammatory responses in-
duced by infection, which can lead to the clearance of
bacteria or pathogens, is a leading cause of death world-
wide [1, 2]. The associated exaggerative immune re-
sponse and pro-inflammatory cytokine overexpression
cause tissue damage and lead to various organ dysfunc-
tions [3]. Neutrophil activity and their recruitment to es-
sential organs such as the lung and liver are crucial for
the immunopathogenesis of severe sepsis [3, 4]. A gram-
negative bacteria-induced sepsis model can be simplified
to induction by lipopolysaccharide (LPS) treatment,
wherein the recruitment of neutrophils to the liver re-
sults in detrimental effects including multi-organ failure
and dysfunction [4, 5].
Mesenchymal stem cells (MSCs) are multipotent stro-
mal cells that have important properties including anti-
apoptotic, angiogenic, growth factor-inducing, anti-
fibrotic, and chemo-attractive activities [6]. MSCs also
have immunomodulatory properties [7, 8], and the bene-
ficial effects of human MSCs on septic mice have been
demonstrated [9, 10]. However, the immunomodulatory
properties of these cells have not been fully elucidated.
Our previous study showed that cord blood-derived
mononuclear cells (MNCs) can differentiate into MSCs
or outgrowth endothelial cells (OECs) [11]. We also
characterized the differentiation potential of CD133+/C-
kit+/Lin− MNCs (CKL− cells) isolated from human um-
bilical cord blood (UCB) and confirmed that CKL− cells
spontaneously differentiate into MSCs or OECs by per-
forming RT-PCR and immunofluorescence staining for
the respective specific markers [11]. Based on the re-
ported beneficial effects of human MSCs against sepsis
[9, 10], we hypothesized that human umbilical cord
blood-derived mesenchymal stem cells (hUCB-MSCs)
could alleviate sepsis-associated acute organ and sys-
temic inflammation via their immunomodulatory prop-
erties to improve survival in LPS-induced sepsis. Next,
we assumed that latent communication mechanisms
such as migration, recruitment, and dissociation between
innate immune cells and hUCB-MSCs might be required
to maintain the immune system balance during sepsis.
For this reason, we monitored dynamic interactions be-
tween innate immune cells such as neutrophils and
hUCB-MSCs in the mouse liver using two-photon intra-
vital imaging. Interestingly, neutrophils can acquire the
capacity to function as antigen-presenting cells (APCs)
under inflammatory conditions or during association
with other cells [12]. In addition, neutrophils have been
reported to express the inherent receptors for antigen
presentation [12]. Therefore, we speculated that the effi-
cacy of hUCB-MSCs in resolving acute inflammation
might be due to immunomodulation through dynamic
interactions with neutrophils. Hence, we aimed to assess
the various biological behaviors of neutrophils and
hUCB-MSCs in a murine sepsis model in real time.
Methods
Mice
Female C57BL/6 mice (Orient Bio, Seongnam, South
Korea) were used for this study. In a preliminary test, we
used both male and female mice; there was no gender
difference in the results of the experiment. LysM-GFP
[13] mice and CX3CR1-GFP mice [14] were obtained.
All mice were maintained under specific-pathogen-free
conditions in the animal establishment at Avison Bio-
medical Research Center in Yonsei University College of
Medicine, and all experiments were approved by the In-
stitutional Animal Care and Use Committee of Yonsei
University Health System (IACUC 2017-0353).
Characterization of hUCB-MSCs
hUCB-MSCs were prepared as described previously [11].
Briefly, CKL− cells were purified by positive and negative
selection with anti-CD133/C-kit/Lin− microbeads (Mil-
tenyi Biotec, Bergisch-Gladbach, Germany) using a mag-
netic cell sorter device (Miltenyi Biotec) from cord
blood samples. CKL− cells were seeded in 6-well plates
coated with human fibronectin (Sigma, St. Louis, MO)
in endothelial basal medium-2 (Clonetics, Cell Systems,
St. Katharinen, Germany). The medium was supple-
mented with endothelial growth medium-2 (EGM-2;
Clonetics, Cell Systems) containing fetal bovine serum,
human VEGF-A, human fibroblast growth factor-B, hu-
man epidermal growth factor, IGF1, and ascorbic acid.
MSCs differentiated from CKL− cells were identified via
staining with PE-CD73, FITC-CD90, and alpha-smooth
muscle actin ( -SMA) (BD Biosciences, Bedford, MA).
MSCs (at 5 × 106 cells/dish) were cultivated in 100-mm
cell culture dishes coated with 0.01mg/mL bovine
plasma-derived fibronectin (R&D systems, Minneapolis,
MN, USA) in endothelial basal medium-2 (EBM-2;
Lonza, Basel, Switzerland). MSCs in all studies were
used at passage < 10. The sampling and use of medical
records for research purpose were performed with the
consent of all patients. This study was approved by the
Yonsei University Hospital Review Board (4-2005-0186).
MSC administration
Before (24 h) LPS injection, saline or MSCs (at 2 × 106
cells/200 μL of saline) were slowly infused via the tail
vein of mice. Mice were randomly assigned to one of
three experimental conditions as follows: (1) saline + sa-
line (control), (2) saline + LPS (LPS-only-treated condi-
tion), (3) hUCB-MSCs + LPS (hUCB-MSC-treated
condition). Finally, for two-photon intravital imaging ex-
periments, an additional condition in which only hUCB-
MSCs were administered was included.
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LPS-induced sepsis
LPS from Salmonella enterica serotype enteritidis was
purified by phenol extraction (Sigma). To induce sepsis,
mice were intraperitoneally injected with LPS at 0.5 mg/
kg 24 h after the i.v. injection of saline or hUCB-MSCs.
Mice were sacrificed 6 h after LPS injection to acquire
tissues and blood for analysis. The lung and liver were
extracted and fixed in 3.7% paraformaldehyde for 24 h.
Whole blood was acquired from mice by cardiac punc-
ture. To obtain plasma, within 30min, samples were
spun down and the supernatant was transferred and
stored at − 80 °C.
Histologic analysis
After fixation, tissues were embedded in paraffin and
sectioned at 4-μm thickness. Hematoxylin and eosin
(H&E) staining was conducted to determine inflamma-
tory morphologic changes and to assess the infiltration
of inflammatory cells in the lung and liver after acute
LPS-induced sepsis. The number of inflammatory cells
was counted in nine randomly chosen histological fields
per section at an original magnification of × 400.
Cytokine and chemokine immunoassay
Whole blood was acquired by cardiac puncture and cen-
trifuged at 2000×g for 20 min at 4 °C. We conducted an
additional centrifugation at 10,000×g for 10 min at 4 °C
for complete platelet removal. Plasma samples were har-
vested using a standard procedure. Plasma separation
tubes (BD, Franklin Lakes, NJ, USA) with lithium hep-
arin and gel were used for plasma collection. Heparin
was used as an anticoagulant. Plasma samples were
stored at − 80 °C for analysis. The plasma samples were
analyzed for IL-1β, IL-6, IL-8, IL-10, TNF-α, IFN-γ, and
CXCL1 via enzyme-linked immunosorbent assay
(ELISA) using mouse-specific kits (R&D systems, Min-
neapolis, MN, USA; MyBioSource, San Diego, CA, USA;
Abcam, Cambridge, UK; and AbFRONTIER, Seoul, Re-
public of Korea).
Survival study
Female C57BL/6 mice (8–14 weeks old) were slowly in-
fused with saline or hUCB-MSCs (at 2 × 106 cells/200 μL
of saline) via i.v. injection. To induce sepsis, mice were
i.p. injected LPS at 25 mg/kg 24 h later. Mice were then
monitored for 6 days.
Fluorescent labeling of MSCs
MSCs were stained with red fluorescence using Cell-
Tracker CMTPX (Thermo, Waltham, MA, USA). Briefly,
harvested and resuspended cells were gently mixed with
pre-warmed CellTracker CMTPX (at 1 μM/2 × 106 cells).
Then, cells were incubated for 20 min at 37 °C.
Two-photon intravital imaging of mouse liver
We previously described a staging system and two-photon
microscopy to obtain imaging data from the live mouse
liver [15, 16]. Two-photon microscopy and Zen software
(Carl-Zeiss, Oberkochen, Germany) were used for mouse
imaging with an imaging chamber. Fluorescence protein-
expressing mice (LysM-GFP and CX3CR1-GFP mice)
were administered saline or red-labeled hUCB-MSCs
(MSCs-CMTPX) 24 h before LPS i.p. injection. Then, LPS
(0.5mg/kg) was injected to induce sepsis 6 h before im-
aging experiments. Mice were anesthetized using Zoletil
at a 30mg/kg via i.p. injection for imaging. Consequently,
two-photon intravital imaging was performed 30 h after
the mice were injected with saline or hUCB-MSCs. The
mouse liver was imaged for approximately 40–50min at a
wavelength 880–900 nm. The images were obtained at a
resolution of 512 × 512 pixels using an interval of 1 μm at
a depth of 40 μm every 60 s.
Imaging data analysis
Analysis of imaging data was conducted using Volocity
(PerkinElmer, Waltham, MA, USA) and Fiji/ImageJ
software.
Statistical analysis
Statistical analyses of data were conducted using Prism 8
software (GraphPad). Quantitative data are expressed as
means and S.D. of at least three independent experi-
ments. The statistical significance of differences among
conditions was determined by a one-way ANOVA with
Dunnett’s post hoc test (for histologic analysis and cyto-
kine and chemokine immunoassays). Survival curves
were analyzed by a log-rank test. Quantitative analyses
of MSCs-CMTPX with LysM-GFP cells were performed
by a one-way ANOVA with Dunnett’s post hoc test or a
Mann–Whitney test for two-photon intravital imaging.
Results
hUCB-MSCs alleviate LPS-induced sepsis
Due to their plasticity and migratory and non-
immunogenic properties, hUCB-MSCs are potentially use-
ful for transplantation and the treatment of many diseases
[17, 18]. To use these cells in a mouse model of disease,
we first cultured hUCB-MSCs and analyzed their charac-
teristics. hUCB-MSCs showed a fibroblastic-like morph-
ology and more spindle-shaped morphology at higher cell
density (Additional file 1: Figure S1a). The spindle-shaped
appearance of hUCB-MSCs is the result of vimentin ex-
pression indicating extracellular matrix synthesis and tis-
sue regeneration [6]. Moreover, hUCB-MSCs expressed
the lineage-specific markers CD73, CD90, and α-SMA
(Additional file 2: Figure S1b). The expression of these
molecules implies the hypo-immunogenicity of hUCB-
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MSCs, which forms an inhibitory milieu surrounding
hUCB-MSCs [19].
Multi-organ dysfunction is induced by the massive re-
cruitment of neutrophils during sepsis and severe sys-
temic inflammatory response syndrome [20]. To
generate an animal sepsis model, hUCB-MSCs were ad-
ministered to mice through i.v. injection 24 h before the
induction of septic conditions through LPS injection
(Fig. 1a). Recently, MSCs have been reported to be effi-
cacious for the treatment of various immune cell
function-related diseases including sepsis [21, 22]. To
evaluate the effect of hUCB-MSC treatment on survival
in LPS-induced septic mice, cells were administered 24 h
before LPS injection (25 mg/kg) (Fig. 1b). Survival was
significantly improved in the hUCB-MSC-treated condi-
tion compared to that in the LPS-only condition, and
there was no significant difference between hUCB-MSC-
treated and control conditions. The 6-day survival rate
of LPS-induced septic mice treated with hUCB-MSCs
was 85.7%, which was significantly higher than 14.3% for
the LPS-only condition. Thus, hUCB-MSC treatment
improved the survival of LPS-induced septic mice.
To determine how hUCB-MSC treatment affects LPS-
induced sepsis, histologic analysis of leukocyte infiltra-
tion was conducted on lung and liver tissues, which were
collected 6 h after LPS injection, and interestingly, sepsis
was attenuated (Fig. 1c). According to a recent study, 6 h
post-LPS injection, treatment with ASCs (adipose-de-
rived mesenchymal stem cells) and educated macro-
phages significantly alleviated the levels of LPS-induced
pro-inflammatory cytokine IFN-γ and IL-6 while in-
creasing the levels of anti-inflammatory cytokine IL-10
in the serum. This phenomenon peaked at 6 h post-LPS
injection and mostly decreased by 48 h [23]. Thus, 6 h
was appropriate as the timeline of administration to de-
termine the effect of MSC in inflammation. Acute organ
inflammation in the LPS-induced septic mice was deter-
mined by counting leukocytes from H&E-stained lung
and liver tissue sections. The number of leukocytes in
the LPS-only condition was markedly increased in al-
veoli of the lung, central vein, and interstitium of the
liver, when compared to that in controls (Fig. 1d). How-
ever, hUCB-MSC treatment significantly decreased these
numbers (Fig. 1d). These data imply that hUCB-MSC
treatment alleviates LPS-induced sepsis.
To further investigate the effect of hUCB-MSCs on
LPS-induced septic conditions, plasma cytokines and
chemokines were assayed 6 h post-LPS injection. Com-
pared to those in controls, levels of pro-inflammatory
cytokines such as IL-1β, IL-6, IL-8, TNF-α, and IFN-γ
were markedly increased with LPS (Fig. 2a). Levels of
the pro-inflammatory chemokine CXCL1 were also
markedly increased (Fig. 2a). In contrast, hUCB-MSC
treatment significantly reduced LPS-induced systemic
cytokine and chemokine (IL-1β, IL-6, IL-8, TNF-α, IFN-
γ, and CXCL1) levels (Fig. 2a). Interestingly, levels of the
anti-inflammatory cytokine IL-10 were increased with
LPS. Moreover, treatment with hUCB-MSCs markedly
elevated IL-10 levels compared to those in the LPS-
treated condition (Fig. 2b). Compared to those in con-
trol, the IL-10 levels significantly increased in the condi-
tion transferred by hUCB-MSC alone, and there was no
significant difference with the LPS-treated condition
(Fig. 2b). Therefore, hUCB-MSCs seem to have immu-
nomodulatory properties through IL-10 expression. To-
gether, our findings verified that hUCB-MSC treatment
mitigates both pro-inflammatory responses and mortal-
ity associated with sepsis.
hUCB-MSCs attenuate the severity of sepsis-related acute
liver injury
The liver is an essential target organ of inflammatory
pathology associated with neutrophils during sepsis and
systemic inflammation [4, 24, 25]. The hepatic sinusoids
that make up most blood vessels in the liver are discon-
tinuous capillaries and are larger in diameter and more
irregular in shape than other types of capillaries. Hence,
the directional migration of neutrophils in hepatic sinu-
soids is less restricted than that in other organs and oc-
curs faster. Therefore, the liver is suitable for monitoring
the migration patterns of innate immune cells such as
neutrophils in inflammatory diseases including sepsis.
Neutrophils are recruited to the sinusoidal capillary of
the liver during inflammation [26, 27]. To investigate the
effect of hUCB-MSCs on neutrophil recruitment under
septic conditions, we performed two-photon intravital
imaging. It has been reported that low concentrations of
LPS (0.5 mg/kg) induce the significant recruitment of
leukocytes into the liver without leukocyte-mediated se-
vere tissue damage and high mortality [4, 24]. In
addition, our preliminary experiments demonstrated that
the number of neutrophils per field of view (FOV)
(mm3) showed no significant difference between the two
different doses (0.5 mg/kg and 25mg/kg) of hUCB-
MSC-treated condition in 24 h post-LPS injection
(Additional file 2: Figure S2a and b; Additional file 18:
Video S15 and Additional file 19: S16). For that reason,
the dose of 0.5 mg/kg was proper to observe the inter-
action between hUCB-MSCs and neutrophils during
sepsis.
Based on two-photon intravital imaging of the liver of
LysM-GFP+/− mice in a time-lapse manner, neutrophils
were mostly observed in the liver bloodstream, but only a
small number of neutrophils were observed in the absence
of LPS treatment (Fig. 3a, upper left panel; Additional file 4:
Video S1). In contrast, LPS-induced sepsis significantly
promoted the recruitment of many neutrophils to the liver
(Fig. 3a, upper right panel; Additional file 5: Video S2).
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Fig. 1 (See legend on next page.)
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The number of neutrophils per field of view (FOV) (mm3)
was markedly higher in the LPS-treated condition than in
control (Fig. 3b). This indicates that LPS-induced sepsis
promotes neutrophil recruitment to the liver. Using two-
photon intravital imaging of the liver in LPS-induced sep-
tic LysM-GFP+/− mice, we observed that the injection of
hUCB-MSCs significantly reduced neutrophil recruitment
compared to that in LPS-only-treated mice (Fig. 3a, lower
left panels; Additional file 5: Video S2 and Additional file 6:
S3). The number of neutrophils per FOV (mm3) was
markedly lower in the hUCB-MSC-treated condition than
in the LPS-treated condition (Fig. 3b). These observations
suggest that fewer neutrophils are recruited to the liver
upon hUCB-MSC treatment.
Neutrophils are mainly recruited by damage-associated
molecular patterns (DAMPs; sterile attack) or pathogen-
associated molecular patterns (PAMPs; microbial attack)
to inflamed areas [28]. PAMPs cause neutrophil recruit-
ment through microbial-induced inflammatory responses
[29]. Therefore, we added a hUCB-MSC-only condition to
confirm that neutrophils recognize hUCB-MSCs as
PAMPs. Interestingly, we found almost no difference in
the hUCB-MSC-only condition compared to that in con-
trol (Fig. 3a, lower right panel; Additional file 7: Video S4).
There was no significant difference in the number of neu-
trophils per FOV (mm3) between the hUCB-MSC-only
and control conditions (Fig. 3b). This finding strongly im-
plies that neutrophils do not recognize hUCB-MSCs as
pathogens.
hUCB-MSCs exert beneficial effects on LPS-induced sepsis
through various migratory behaviors with neutrophils
MSCs stimulated by LPS induce the recruitment of neu-
trophils through the secretion of IL-8 and macrophage
migration inhibitory factor (MIF) [30]. Indeed, we demon-
strated that after LPS administration, more neutrophils
were notably recruited to the liver in the hUCB-MSC-
treated condition than in the hUCB-MSC-only condition
(Fig. 3a, lower panels; Additional file 6: Videos S3 and
Additional file 7: S4). It has been reported that many i.v.
injected hMSCs remain mostly intact despite repeated
contact with host neutrophils. However, some hMSCs are
cleaved and subsequently phagocytized by surrounding
GFP+ granulocytes in the LPS-stimulated LysM-GFP+/−
mice [31]. In the hUCB-MSC-treated condition, we ana-
lyzed dynamic interactions between neutrophils and
hUCB-MSCs in the inflamed liver of LysM-GFP+/− mice.
We observed that neutrophils migrated toward hUCB-
MSCs when stimulated with LPS (Fig. 4a; Additional file 8:
Video S5). Some neutrophils gathering toward hUCB-
MSCs attempted to phagocytize hUCB-MSCs (Fig. 4b;
Additional file 9: Video S6 and Additional file 10: S7).
Subsequently, neutrophils that engulfed some hUCB-
MSCs migrated from the original site to another site
(Fig. 4c; Additional file 11: Video S8). After cleavage by
neutrophils, the cellular debris of hUCB-MSCs were
observed as particles engulfed by neutrophils. These neu-
trophils showed a significant increase in the contact
frequency with other adjacent neutrophils (Fig. 4d;
Additional file 12: Video S9). According to quantitative
analysis, the relative contact frequency among the neutro-
phils was markedly increased 6 h after LPS administration
in the hUCB-MSC-treated condition compared to that in
the hUCB-MSC-only condition (Fig. 4e). This unique
phenomenon is the result of neutrophil stimulation by ac-
tivated MSCs through microbial triggering [32]. Inte-
restingly, neutrophils can survive much longer while
interacting with other cells or under pathological condi-
tions such as sepsis [12]. Indeed, more neutrophils gath-
ered around hUCB-MSCs that were not entirely engulfed
by numerous neutrophils for several hours during imaging
(Fig. 4f; Additional file 13: Video S10 and Additional file 14:
S11). In this experiment, we defined the early phase as 4
min and the late phase as 68min during imaging (Fig. 4f;
Additional file 13: Video S10). Quantitative analysis
showed that the number of neutrophils while swarming was
significantly increased in the late phase compared to that in
the early phase (Fig. 4g). This swarm-like migration pattern
of neutrophils is called “neutrophil swarming” [33]. This ob-
servation could suggest that neutrophils induce swarming
behavior through continuous contact or paracrine effects
among neutrophils. Several studies have reported that neu-
trophils are selectively recruited by LPS-stimulated MSCs
through paracrine effects. Thus, LPS-triggered MSCs select-
ively attract neutrophils, thereby strengthening the function
and survival of neutrophils [30, 34]. These data indicate that
(See figure on previous page.)
Fig. 1 Effects of hUCB-MSC treatment on LPS-induced sepsis. a Schematic diagram of the study. Saline or a suspension of hUCB-MSCs was slowly
infused into tail veins. Mice with sepsis were intraperitoneally induced with 0.5 or 25 (for survival study) mg/kg of LPS 24 h after hUCB-MSC
administration, and 6 h later, they were sacrificed for in vivo experiments or were visualized by two-photon intravital imaging. b hUCB-MSC
treatment significantly improved survival in the hUCB-MSC-treated condition compared to that in the LPS-only condition. hUCB-MSCs were
administered 24 h prior to LPS (25 mg/kg) treatment. Mice were monitored for 6 days; n = 7 for each condition. Kaplan–Meier curves were
analyzed by a log-rank test. *p < 0.05, **p < 0.005. c Pathological inflammatory changes in lung (alveoli) and liver (central vein and interstitium)
tissues were shown by H&E staining (original magnification, × 400; scale bar = 50 μm). d The graphs show the number of leukocytes for each
condition relative to that in control lung (alveoli) and liver (central vein and interstitium) tissues. Quantitative results indicate the average values ±
SD of at least three independent experiments. The results were analyzed by a one-way ANOVA with Dunnett’s post hoc test. *p < 0.01
and **p < 0.005 versus control; ***p < 0.001 versus each condition
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hUCB-MSCs have beneficial effects on LPS-induced sepsis
through various biological behaviors in association with
neutrophils.
HSCs enhance the therapeutic effects on LPS-induced
sepsis by hUCB-MSCs
Hepatic stellate cells (HSCs) are located in the suben-
dothelial space called the space of Disse, between hepa-
tocytes and liver sinusoidal endothelial cells (LSECs)
[35]. HSCs have a stellate phenotype characterized by
several dendritic processes [35]. In a steady state, HSCs
store vitamin A in cytoplasmic lipid droplets. However,
in pathological conditions such as hepatic fibrosis and
cirrhosis, HSCs lose lipid and vitamin A storage ability
and are transformed into myofibroblasts. This change
into collagen-producing cells leads to portal hyperten-
sion [36], which provides evidence that HSCs perform
an essential role in liver immune functions. Hence, it is
crucial to investigate interactions between HSCs and
hUCB-MSCs in liver immunobiology. To examine any
correlation between HSCs and hUCB-MSCs in the liver
during LPS-induced sepsis, we performed two-photon
intravital imaging 30 h after hUCB-MSC administration
in CX3CR1-GFP+/− mice with LPS treatment for 6 h. Re-
cent studies have shown monocyte-derived CX3CR1+
LCMs (liver capsular macrophages) [37] and resident
CX3CR1+ HSCs [4] in the inflamed liver of CX3CR1-
GFP+/− mice. Our preliminary experiments demon-
strated that LCMs occupied the hepatic capsule with
mostly second harmonic generation (SHG) in the in-
flamed liver of CX3CR1-GFP+/− mice. Second harmonic
generation (SHG) has been used to see fibrillar collagen
structures in connective tissues in vivo experiments
using two-photon intravital imaging [38]. On the other
hand, HSCs were located in the space of Disse in the in-
flamed liver of CX3CR1-GFP+/− mice (Additional file 3:
Figure S3a; Additional file 20: Video S17 and Add-
itional file 21: S18). However, we did not detect any not-
able differences in biological behaviors between LCMs
and hUCB-MSCs in the liver of CX3CR1-GFP+/− mice
under both physiological and pathological conditions
(data not shown). This observation indicates that hUCB-
MSC efficacy in mitigating sepsis might be due to inter-
actions with other immune cells rather than monocyte-
derived macrophages in the liver. HSCs have been re-
ported to undergo direct contact with disease-associated
lymphocytes [39]. HSCs represent 5–8% of hepatic cells
in a steady state [40]. Under pathological conditions
such as tissue injury and inflammation, HSCs transdif-
ferentiate into a myofibroblast-like phenotype [41–43].
Based on two-photon intravital imaging of the liver of
CX3CR1-GFP+/− mice in a time-lapse manner, a few
HSCs were mainly observed in the subendothelial space
in the absence of LPS treatment (Additional file 3:
Figure S3b, upper left panel; Additional file 22:
Video S19). Indeed, LPS-induced sepsis certainly pro-
moted the transdifferentiation of HSCs into
myofibroblast-like cells (Additional file 3: Figure S3b,
upper right panel, Additional file 23: Video S20). However,
the number of HSCs was not significantly different in the
LPS-treated condition compared to that in control. This
indicates that LPS-induced sepsis promotes HSC transdif-
ferentiation into myofibroblast-like cells. Next, we found
almost no difference for transdifferentiation capacity of
HSCs in the hUCB-MSC-treated condition compared
to that in the LPS-treated condition (Additional file 3:
Figure S3b, lower left panels; Additional file 23: Video
S20 and Additional file 24: S21). According to a pre-
vious study, HSCs have been reported to contact a
large number of hepatocytes, adjacent stellate cells,
endothelial cells, and nerve endings using their cyto-
plasmic processes [44]. Actually, in the hUCB-MSC-
treated condition, we observed vigorous interactions be-
tween HSCs and hUCB-MSCs in the liver of CX3CR1-
GFP+/− mice. During imaging, we observed direct contact
between HSCs and hUCB-MSCs through repeated den-
drite movements such as extension and retraction in
HSCs (Fig. 5a; Additional file 15: Video S12). We also ob-
served distinct differences in HSC motility between
physiological and pathological conditions. First, HSCs
engulfing hUCB-MSCs were highly motile and actively
crawled through the interstitial tissue of the liver under
physiological conditions (Fig. 5b; Additional file 16:
Video S13). Second, completely immobile HSCs engulfed
hUCB-MSCs under pathological conditions induced by
LPS stimulation (Fig. 5c; Additional file 17: Video S14).
Interestingly, we observed that the transdifferentiation
capacity of HSCs notably decreased in the hUCB-MSC-
only condition compared to that in LPS-only and hUCB-
MSC-treated conditions (Additional file 3: Figure S3b,
lower right panel; Additional file 25: Video S22). This
finding implies that HSCs do not recognize hUCB-MSCs
as foreign in the mouse body and consequently do not
cause graft rejection. In addition, under physiological con-
ditions, there was no significant difference in the motility
of MSC debris-containing (Fig. 5b; Additional file 16:
(See figure on previous page.)
Fig. 2 Effects of hUCB-MSC treatment on LPS-induced systemic sepsis and survival. a The levels of the pro-inflammatory cytokines and a
chemokine (IL-1β, IL-6, IL-8, TNF-α, IFN-γ, and CXCL1) in the plasma. b Levels of the anti-inflammatory cytokine IL-10 in the plasma were
measured by immunoassay. Quantitative results indicate the average values ± SD of at least three independent experiments. The results were
analyzed by a one-way ANOVA with Dunnett’s post hoc test. *p < 0.005, **p < 0.001
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Video S13) and debris-free HSCs (Additional file 3: Figure
S3b, upper left panel; Additional file 22: Video S19). These
observations suggest that the factor of affecting the trans-
differentiation and motility of HSCs is not the hUCB-
MSCs but the inflammatory environment such as sepsis.
According to recent researches, HSCs do not function as
APCs under physiological conditions, but this situation
has changed in the inflamed liver. Exposure of HSCs to
the inflammatory environment changes the morphology
of HSCs, strengthening their capacity to present antigen
to lymphocytes [45–47]. As a result, HSCs are crucial
players to resolve the pathological conditions such as hep-
atic fibrosis, cirrhosis, and bacterial infection in the liver.
These data indicate that HSCs may enhance the thera-
peutic effects on LPS-induced sepsis by hUCB-MSCs.
Therefore, we plan to study the role of HSCs in diverse in-
flammatory diseases of the liver in future researches.
Discussion
Sepsis is characterized by an overwhelming systemic in-
flammatory response due to the PAMPs from invading
microorganisms or injured host tissue [48]. PAMPs bind
to pattern recognition receptors (PRRs) expressed on in-
nate immune cells, which leads to a hyper-inflammatory
response [49]. The activation of PRRs promotes the pro-
duction of diverse pro-inflammatory molecules such as
IL-1β, IL-2, IL-6, IL-8, TNF-α, and IFN-γ and anti-
inflammatory cytokines such as IL-10 [34]. This exaggera-
tive production of pro- and anti-inflammatory cytokines
and chemokines lead to the “cytokine storm” phase caus-
ing severe inflammatory responses [50]. MSC treatment
against excessive inflammatory responses has been associ-
ated with alleviated systemic pro-inflammatory cytokines,
attenuated organ injury, and improved survival in both
microbial and polymicrobial sepsis models [51, 52]. We
confirmed similar efficacy for hUCB-MSC treatment in
microbial sepsis-induced morbidity and mortality. Inter-
estingly, a number of studies have shown that the benefi-
cial effects of MSCs on LPS- or cecal ligation and
puncture (CLP)-induced sepsis are linked to an increase
in the anti-inflammatory cytokine IL-10 [9, 53]. We also
observed that systemic IL-10 levels were markedly ele-
vated by hUCB-MSC treatment. Hereby, in this study, we
demonstrated that hUCB-derived MSCs modulate
neutrophil migration and improve survival in a microbial
sepsis model induced by LPS treatment. This alleviation
may result from the immunomodulatory properties of
hUCB-MSCs. Several studies have shown that neutrophils
can acquire the capacity to function as APCs under in-
flammatory conditions or during associations with other
cells [12, 54]. Thus, these observations suggest that neu-
trophils mediate innate and adaptive immunity by increas-
ing contact frequency with other cells. Several studies
have shown that MSCs have immunosuppressive and im-
munomodulatory functions. This MSC-mediated immune
suppression and modulation has been reported to enable
immune evasion [55, 56]. The enhanced immunosuppres-
sive properties of MSCs allow them to mitigate inflamma-
tion and delay or avoid host immune rejection by
inhibiting T cell responses and suppressing APC matur-
ation [57, 58]. This observation could suggest that hUCB-
MSCs have host innate immune evasion or resistance
capacity.
HSCs are astral cells that reside in the space of Disse.
These HSCs constitute as little as 5–8% of whole liver cells
[59]. They also perform a critical role as immune sentinels
of the liver [35] and activated HSCs induce hepatic inflam-
mation through expressing MCP-1 [60] and IL-6 [61]. Acti-
vated HSCs secrete numerous pro-inflammatory cytokines
and chemokines with chemoattractant activity toward
leukocytes [47, 60, 62]. Activated HSCs also have been re-
ported to highly express HLA family molecules (predomin-
antly HLA class II) and CD40 for antigen presentation [63].
According to previous studies, HSCs function as nonprofes-
sional APCs such as LSECs [63]. Whereas professional
APCs have immune properties under physiological condi-
tions, nonprofessional APCs mainly obtain such character-
istics under pathological conditions. Nonprofessional APCs
support the immune system in inflamed tissues with in-
crease pro-inflammatory cytokine and chemokine produc-
tion. For example, HSCs can phagocytose macromolecules
and bacteria [63]. Indeed, we observed that HSCs directly
contact hUCB-MSCs through repeated dendrite move-
ments such as extension and retraction in HSCs. Previous
studies have shown that skin dendritic cells (termed Lang-
erhans) and microglial cells function as sentinels against in-
vading microorganisms showing similar dendrite behaviors,
termed “dSEARCH (dendrite surveillance extension and
(See figure on previous page.)
Fig. 3 Two-photon intravital microscopy of neutrophils and hUCB-MSC interactions in the liver of LysM-GFP+/− mice. a Representative images for
each condition; (upper panel) red: hepatic microvasculature (Texas Red-Dextran signal); green: neutrophils (endogenous signal), (lower panel) red:
CMTPX-labeled hUCB-MSCs (exogenous signal); green: neutrophils (endogenous signal). Conditions included control (Additional file 4: Video S1),
LPS (LPS-only-treated; Additional file 5: Video S2), hUCB-MSCs + LPS (hUCB-MSCs-treated; Additional file 6: Video S3), and hUCB-MSCs (hUCB-MSCs
only treated; Additional file 7: Video S4). The “guiding arrows” represent neutrophils in control and hUCB-MSC conditions. These data are
representative of three independent experiments (original magnification, × 200; scale bar = 30 μm). b The graph shows the number of neutrophils
per FOV (mm3) for each condition in a. Quantitative results indicate the average values ± SD of at least three independent experiments. The
results were analyzed by a one-way ANOVA with Dunnett’s post hoc test. *p < 0.01 versus control, **p < 0.001 versus each condition
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retraction cycling habitude)” [37]. In this study, HSCs did
not recognize hUCB-MSCs as foreign in the mouse body
and consequently did not cause graft rejection. These find-
ings indicate that HSCs may enhance the therapeutic effects
on LPS-induced sepsis by hUCB-MSCs.
Over the past few years, clinical trials with MSC ther-
apy have been reported in diverse inflammatory diseases
such as various autoimmune diseases [64, 65], graft-
versus-host disease (GvHD) [66], ulcerative colitis [34],
acute respiratory distress syndrome (ARDS) [67], and sep-
tic shock [50]. Despite numerous studies on their efficacy,
the mechanism underlying the therapeutic effects of
MSCs in diverse inflammatory diseases has not yet been
fully elucidated. However, an understanding of the im-
portance of the immunomodulatory properties of MSCs
for sepsis treatment is becoming elucidated [55, 68]. Ac-
cording to previous studies, these immunomodulatory
properties also enable immune evasion from the host
(See figure on previous page.)
Fig. 4 Dynamic interactions between neutrophils and hUCB-MSCs in the inflamed liver of LysM-GFP+/− mice using two-photon intravital
microscopy. Representative images of dynamic interactions; red: CMTPX-labeled hUCB-MSCs (exogenous signal); green: neutrophils (endogenous
signal). a Neutrophils migrated toward the activated hUCB-MSCs upon LPS stimulation (Additional file 8: Video S5). b Neutrophils gathering
toward hUCB-MSCs attempted to phagocytize hUCB-MSCs (Additional file 9: Video S6 and Additional file 10: S7). c Neutrophils that engulfed
some hUCB-MSCs migrated from the original site to another site (Additional file 11: Video S8). d Neutrophils showed a significant increase in
contact frequency with other adjacent neutrophils (Additional file 12: Video S9). e The graph shows the relative contact frequency between
neutrophils per FOV (mm3) in the hUCB-MSC-treated condition (hUCB-MSC only versus hUCB-MSC + LPS). f The early phase (4 min) and late
phase (68 min) of neutrophil swarming (Additional file 13: Video S10 and Additional file 14: S11). g The graph shows the number of neutrophils
per FOV (mm3) during neutrophil swarming (early phase versus late phase). Quantitative results indicate the average values ± SD of at least three
independent experiments. The results were analyzed by Mann–Whitney test. **p < 0.001 versus each condition. These data are representative of
three independent experiments (original magnification, × 200; scale bar = 10 μm)
Fig. 5 Vigorous interactions between HSCs and hUCB-MSCs in the liver of CX3CR1-GFP+/− mice. a Representative time-lapse images showing that
HSCs formed extended and retracted dendrites toward hUCB-MSCs. Imaging times (white dotted line: morphology of HSC; yellow dotted line:
extended dendrites of HSC; scale bar = 20 μm; Additional file 15: Video S12) are represented. b Representative time-lapse images showing that
migratory HSCs engulfed hUCB-MSCs under physiological conditions. Imaging times (scale bar = 20 μm; Additional file 16: Video S13) are
represented. c Representative time-lapse images showing the immobile HSCs that engulfed hUCB-MSCs under pathological conditions (including
LPS stimulation). Red: CMTPX-labeled hUCB-MSCs (exogenous signal); green: resident CX3CR1+ HSCs (endogenous signal). Imaging times (scale
bar = 20 μm; Additional file 17: Video S14) are represented. Data are representative of three independent experiments (original
magnification, × 200)
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immune system [55, 56]. Similar to these studies, the im-
munomodulatory properties of hUCB-MSCs are required
for their proper application to inflammatory responses. Par-
ticularly, the persistence of MSC effects is correlated with
the rate of immune detection [55]. The rates of MSC im-
mune detection and elimination are governed by a balance
between the relative expression of immunogenic and im-
munomodulatory factors in MSCs. In other words, a
decrease in immunogenic factors [18] leads to slower im-
mune detection [55]. Together, the immunomodulatory
properties of MSCs enable evasion from immune rejection
responses. In fact, graft rejection is a common phenomenon
when human cells are injected into a mouse. However, in
our experiments with hUCB-MSCs, we hardly detected
such graft rejection. In clinical trials of MSCs for sepsis
treatment, the rejection of transplanted cells occurs less
often and later than that of other transplanted tissues. For
this reason, cellular therapy using the immunomodulatory
properties of MSCs for sepsis treatment could be favorable.
Conclusion
This study is significant as it shows biological behaviors
of neutrophils and hUCB-MSCs in live murine sepsis
model in a real-time manner. Further, our research
would contribute to future studies on the mechanism
underlying neutrophil and MSC interactions with re-
spect to the treatment of sepsis.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13287-020-1559-4.
Additional file 1: Figure S1. Characterization of hUCB-MSC. a. In vitro
culture, hUCB-MSC morphology. Low density and high density hUCB-
MSCs (original magnification × 100; scale bar = 200 μm). b. hUCB-MSCs
were characterized by flow cytometry and immunofluorescent staining
for CD73, CD90, and α-SMA.
Additional file 2: Figure S2. Neutrophils and hUCB-MSCs interactions
in the inflamed liver between the two different LPS doses (0.5 mg/kg and
25 mg/kg) of LysM-GFP+/− mice. a. Representative images for each dose;
red: CMTPX-labeled hUCB-MSCs (exogenous signal); green: neutrophils
(endogenous signal). The two different LPS doses (0.5 mg/kg and 25 mg/
kg) of hUCB-MSCs-treated condition in 24 h post-LPS injection. The 0.5
mg/kg of LPS (Video S15) and 25 mg/kg of LPS (Video S16). These data
are representative of three independent experiments (original magnification,
× 200; scale bar = 30 μm). b. The graph shows the number of neutrophils
per FOV (mm3) for each dose (mpk = mg/kg; n.s. = not significant).
Quantitative results indicate the average values ± SD of at least three
independent experiments. The results were analyzed by a Mann-
Whitney test.
Additional file 3: Figure S3. Liver capsular macrophages (LCMs) and
Hepatic stellate cells (HSCs) in the liver of CX3CR1-GFP+/− mice. a.
Representative images for LCMs and HSCs (Video S17 and S18); blue:
second harmonic generation (SHG, endogenous signal); green: LCMs (left
panel) and HSCs (right panel) (endogenous signal). b. Representative
images for each condition; red: CMTPX-labeled hUCB-MSCs (exogenous
signal); blue: second harmonic generation (SHG, endogenous signal);
green: HSCs (endogenous signal). Conditions included control (Video
S19), LPS (LPS-only-treated; Video S20), hUCB-MSCs + LPS (hUCB-MSCs-
treated; Video S21), and hUCB-MSCs (hUCB-MSCs only treated; Video S22).
The “guiding arrows” represent HSCs in Figure S3a and b. These data are
representative of three independent experiments (original magnification,
× 200; scale bar = 40 μm).
Additional file 4: Video S1. Two-photon intravital image of control
condition in the liver of LysM-GFP+/− mice.
Additional file 5: Video S2. Two-photon intravital image of LPS-only
treated condition in the liver of LysM-GFP+/− mice.
Additional file 6: Video S3. Two-photon intravital image of hUCB-
MSCs + LPS condition in the liver of LysM-GFP+/− mice.
Additional file 7: Video S4. Two-photon intravital image of hUCB-
MSCs only condition in the liver of LysM-GFP+/− mice.
Additional file 8: Video S5. Two-photon intravital image showed that
neutrophils migrated toward hUCB-MSCs after LPS stimulation.
Additional file 9: Video S6. Two-photon intravital image showed that
neutrophils gathered toward hUCB-MSCs attempted to phagocytize
hUCB-MSCs.
Additional file 10: Video S7. Three-dimensional image of video S6 at a
timepoint.
Additional file 11: Video S8. Two-photon intravital image showed that
neutrophil engulfed hUCB-MSCs migrated from the original site to
another site.
Additional file 12: Video S9. Two-photon intravital image showed that
neutrophils having hUCB-MSCs showed frequent contacts with adjacent
other neutrophils.
Additional file 13: Video S10. Two-photon intravital image of swarm-
like migration pattern of neutrophils.
Additional file 14: Video S11. Three-dimensional image of video S10
at a timepoint.
Additional file 15: Video S12. Two-photon intravital image showed
that HSCs formed repeated dendrite movement toward hUCB-MSCs
(Repeated dendrites movement).
Additional file 16: Video S13. Two-photon intravital image showed
that migratory HSCs engulfed hUCB-MSCs under physiological conditions.
Additional file 17: Video S14. Two-photon intravital image showed
that completely immobile HSCs engulfed hUCB-MSCs under LPS
stimulation.
Additional file 18: Video S15. Two-photon intravital image of hUCB-
MSCs + LPS (0.5 mg/kg) condition in the liver of LysM-GFP+/− mice.
Additional file 19: Video S16. Two-photon intravital image of hUCB-
MSCs + LPS (25 mg/kg) condition in the liver of LysM-GFP+/− mice.
Additional file 20: Video S17. Two-photon intravital image of LCMs in
the liver of CX3CR1-GFP+/− mice.
Additional file 21: Video S18. Two-photon intravital image of HSCs in
the liver of CX3CR1-GFP+/− mice.
Additional file 22: Video S19. Two-photon intravital image of control
condition in the liver of CX3CR1-GFP+/− mice.
Additional file 23: Video S20. Two-photon intravital image of LPS-only
treated condition in the liver of CX3CR1-GFP+/− mice.
Additional file 24: Video S21. Two-photon intravital image of hUCB-
MSCs + LPS condition in the liver of CX3CR1-GFP+/− mice.
Additional file 25: Video S22. Two-photon intravital image of hUCB-
MSCs only condition in the liver of CX3CR1-GFP+/− mice.
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